Donepezil Hydrochloride Activase Pharmaceutical (Donepezil Hydrochloride)

Donepezil Hydrochloride is primarily indicated for the symptomatic treatment of cognitive decline associated with Alzheimer’s disease.

• Mild to moderate Alzheimer’s disease, to improve cognition and daily functioning.
• Adjunct therapy in patients with early-stage disease when combined with non‑pharmacologic interventions.
• May be considered for patients with moderate disease who retain some functional abilities.
• Used off‑label in some clinical settings for research on cholinergic modulation.
• May be prescribed to support patients transitioning from other cholinesterase inhibitors.
• Can be part of a comprehensive care plan that includes lifestyle and cognitive support.

Side effects of donepezil hydrochloride vary in frequency and severity; they are reported in clinical trials and post‑marketing experience.

Common

• Nausea or vomiting.
• Diarrhea.
• Insomnia or abnormal dreams.
• Muscle cramps or fatigue.

Serious

• Bradycardia or heart block.
• Severe gastrointestinal bleeding.
• Allergic reactions such as rash, angioedema, or anaphylaxis.

When prescribing donepezil hydrochloride, clinicians should consider several precautions to ensure safe use and monitor for potential complications.

• Assess cardiac history, especially bradyarrhythmias, before initiating therapy.
• Evaluate hepatic function; dose adjustments may be needed in severe liver impairment.
• Monitor for gastrointestinal ulceration or bleeding, particularly in patients on NSAIDs or anticoagulants.
• Use caution in patients with a history of seizures or epilepsy.
• Review concomitant medications that affect cholinergic pathways.
• Consider pregnancy and lactation status, as safety data are limited.

Donepezil hydrochloride can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Concurrent use with strong anticholinergic agents (e.g., atropine, scopolamine) may reduce therapeutic effect.
• Combined use with other acetylcholinesterase inhibitors (e.g., rivastigmine, galantamine) is not recommended.
• Co‑administration with drugs that prolong the QT interval should be avoided due to additive cardiac risk.

Use with caution

• NSAIDs, aspirin, or anticoagulants may increase risk of gastrointestinal bleeding; monitor closely.
• Beta‑blockers or calcium channel blockers may exacerbate bradycardia; observe heart rate.
• CYP3A4 or CYP2D6 inhibitors (e.g., ketoconazole, fluoxetine) can raise donepezil levels; dose adjustment may be needed.